Relapsed/refractory multiple myeloma for which a new high-dose chemotherapy and autologous re-transplantation has taken place
Conditions
Interventions
Group 1: The study population consists of patients of age >18 years with refractory or relapsed multiple myeloma who have received high-dose chemotherapy and autologous stem cell transplantation as pa
Sponsors
Klinikum Chemnitz gGmbH
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Relapsed or refractory multiple myeloma patients who have already received high-dose chemotherapy and autologous stem cell transplantation as part of the initial therapy and who have received high-dose chemotherapy and autologous stem cell transplantation again in the event of relapse or refractory disease
Exclusion criteria
Exclusion criteria: Patients who received the autologous re-transplantation as part of a so-called auto-allo concept are excluded from the evaluation, i.e. an allogeneic stem cell transplantation was performed shortly after the autologous re-transplantation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The influence of risk factors (genetic changes in plasma cells, R-ISS stage at initial and relapse diagnosis and PFS after first high-dose chemotherapy and autologous stem cell transplantation) and prior therapy on response rates according to IMWG criteria, progression-free time and overall survival will be evaluated. | — |
Secondary
| Measure | Time frame |
|---|---|
| In addition, demographic and clinical data will be evaluated with regard to their influence on the study results. Response rates, PFS and OS from this study will be evaluated in the context of the existing literature. Furthermore, data on the toxicity of the therapy will be collected. | — |
Countries
Germany
Contacts
Public ContactMathias Hänel
Klinikum Chemnitz gGmbH
Outcome results
None listed